Financhill
Sell
14

HOOK Quote, Financials, Valuation and Earnings

Last price:
$1.22
Seasonality move :
-19.38%
Day range:
$1.16 - $1.22
52-week range:
$0.72 - $6.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.62x
P/B ratio:
0.43x
Volume:
50.5K
Avg. volume:
61.1K
1-year change:
-76.24%
Market cap:
$14.7M
Revenue:
$43.9M
EPS (TTM):
-$5.84

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HOOK
HOOKIPA Pharma
$3.4M -$0.64 161.63% -59.87% $2.00
GILD
Gilead Sciences
$7B $1.97 -0.13% 51.38% $116.96
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
POAI
Predictive Oncology
$1.5M -- -25.85% -- --
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
VIGL
Vigil Neuroscience
-- -$0.47 -- -9.62% $9.52
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HOOK
HOOKIPA Pharma
$1.21 $2.00 $14.7M -- $0.00 0% 1.62x
GILD
Gilead Sciences
$113.24 $116.96 $140.9B 23.84x $0.79 2.76% 4.97x
NBY
NovaBay Pharmaceuticals
$0.65 $0.85 $3.8M -- $0.00 0% 0.16x
POAI
Predictive Oncology
$0.80 -- $7.1M -- $0.00 0% 3.70x
TOVX
Theriva Biologics
$0.47 $7.00 $3.8M -- $0.00 0% 0.33x
VIGL
Vigil Neuroscience
$8.01 $9.52 $373.8M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HOOK
HOOKIPA Pharma
-- 3.199 -- 2.92x
GILD
Gilead Sciences
56.56% 0.135 17.9% 1.00x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
POAI
Predictive Oncology
-- 0.261 -- 0.68x
TOVX
Theriva Biologics
-- -3.388 -- --
VIGL
Vigil Neuroscience
-- 10.653 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HOOK
HOOKIPA Pharma
-- -$17.5M -105.09% -105.43% -769.81% $32K
GILD
Gilead Sciences
$5.1B $2.5B 13.82% 32.29% 28.63% $1.7B
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
POAI
Predictive Oncology
$65.2K -$2.3M -529.75% -557.45% -2073.29% -$985.8K
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M
VIGL
Vigil Neuroscience
-- -$23.5M -- -- -- -$24.2M

HOOKIPA Pharma vs. Competitors

  • Which has Higher Returns HOOK or GILD?

    Gilead Sciences has a net margin of -769.81% compared to HOOKIPA Pharma's net margin of 19.72%. HOOKIPA Pharma's return on equity of -105.43% beat Gilead Sciences's return on equity of 32.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    HOOK
    HOOKIPA Pharma
    -- -$1.23 $34.1M
    GILD
    Gilead Sciences
    76.9% $1.04 $44B
  • What do Analysts Say About HOOK or GILD?

    HOOKIPA Pharma has a consensus price target of $2.00, signalling upside risk potential of 65.29%. On the other hand Gilead Sciences has an analysts' consensus of $116.96 which suggests that it could grow by 3.29%. Given that HOOKIPA Pharma has higher upside potential than Gilead Sciences, analysts believe HOOKIPA Pharma is more attractive than Gilead Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    HOOK
    HOOKIPA Pharma
    0 1 0
    GILD
    Gilead Sciences
    16 11 0
  • Is HOOK or GILD More Risky?

    HOOKIPA Pharma has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

  • Which is a Better Dividend Stock HOOK or GILD?

    HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.76% to investors and pays a quarterly dividend of $0.79 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

  • Which has Better Financial Ratios HOOK or GILD?

    HOOKIPA Pharma quarterly revenues are $2M, which are smaller than Gilead Sciences quarterly revenues of $6.7B. HOOKIPA Pharma's net income of -$15.4M is lower than Gilead Sciences's net income of $1.3B. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 23.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 1.62x versus 4.97x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HOOK
    HOOKIPA Pharma
    1.62x -- $2M -$15.4M
    GILD
    Gilead Sciences
    4.97x 23.84x $6.7B $1.3B
  • Which has Higher Returns HOOK or NBY?

    NovaBay Pharmaceuticals has a net margin of -769.81% compared to HOOKIPA Pharma's net margin of -49.65%. HOOKIPA Pharma's return on equity of -105.43% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    HOOK
    HOOKIPA Pharma
    -- -$1.23 $34.1M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About HOOK or NBY?

    HOOKIPA Pharma has a consensus price target of $2.00, signalling upside risk potential of 65.29%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.89%. Given that HOOKIPA Pharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe HOOKIPA Pharma is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    HOOK
    HOOKIPA Pharma
    0 1 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is HOOK or NBY More Risky?

    HOOKIPA Pharma has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock HOOK or NBY?

    HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HOOK or NBY?

    HOOKIPA Pharma quarterly revenues are $2M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. HOOKIPA Pharma's net income of -$15.4M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 1.62x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HOOK
    HOOKIPA Pharma
    1.62x -- $2M -$15.4M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns HOOK or POAI?

    Predictive Oncology has a net margin of -769.81% compared to HOOKIPA Pharma's net margin of -2214.55%. HOOKIPA Pharma's return on equity of -105.43% beat Predictive Oncology's return on equity of -557.45%.

    Company Gross Margin Earnings Per Share Invested Capital
    HOOK
    HOOKIPA Pharma
    -- -$1.23 $34.1M
    POAI
    Predictive Oncology
    59.1% -$0.34 -$145.8K
  • What do Analysts Say About HOOK or POAI?

    HOOKIPA Pharma has a consensus price target of $2.00, signalling upside risk potential of 65.29%. On the other hand Predictive Oncology has an analysts' consensus of -- which suggests that it could grow by 275%. Given that Predictive Oncology has higher upside potential than HOOKIPA Pharma, analysts believe Predictive Oncology is more attractive than HOOKIPA Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    HOOK
    HOOKIPA Pharma
    0 1 0
    POAI
    Predictive Oncology
    0 0 0
  • Is HOOK or POAI More Risky?

    HOOKIPA Pharma has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison Predictive Oncology has a beta of 1.176, suggesting its more volatile than the S&P 500 by 17.559%.

  • Which is a Better Dividend Stock HOOK or POAI?

    HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Predictive Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. Predictive Oncology pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HOOK or POAI?

    HOOKIPA Pharma quarterly revenues are $2M, which are larger than Predictive Oncology quarterly revenues of $110.3K. HOOKIPA Pharma's net income of -$15.4M is lower than Predictive Oncology's net income of -$2.4M. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while Predictive Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 1.62x versus 3.70x for Predictive Oncology. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HOOK
    HOOKIPA Pharma
    1.62x -- $2M -$15.4M
    POAI
    Predictive Oncology
    3.70x -- $110.3K -$2.4M
  • Which has Higher Returns HOOK or TOVX?

    Theriva Biologics has a net margin of -769.81% compared to HOOKIPA Pharma's net margin of --. HOOKIPA Pharma's return on equity of -105.43% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HOOK
    HOOKIPA Pharma
    -- -$1.23 $34.1M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About HOOK or TOVX?

    HOOKIPA Pharma has a consensus price target of $2.00, signalling upside risk potential of 65.29%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1388.73%. Given that Theriva Biologics has higher upside potential than HOOKIPA Pharma, analysts believe Theriva Biologics is more attractive than HOOKIPA Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    HOOK
    HOOKIPA Pharma
    0 1 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is HOOK or TOVX More Risky?

    HOOKIPA Pharma has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock HOOK or TOVX?

    HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HOOK or TOVX?

    HOOKIPA Pharma quarterly revenues are $2M, which are larger than Theriva Biologics quarterly revenues of --. HOOKIPA Pharma's net income of -$15.4M is lower than Theriva Biologics's net income of -$4.3M. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 1.62x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HOOK
    HOOKIPA Pharma
    1.62x -- $2M -$15.4M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M
  • Which has Higher Returns HOOK or VIGL?

    Vigil Neuroscience has a net margin of -769.81% compared to HOOKIPA Pharma's net margin of --. HOOKIPA Pharma's return on equity of -105.43% beat Vigil Neuroscience's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HOOK
    HOOKIPA Pharma
    -- -$1.23 $34.1M
    VIGL
    Vigil Neuroscience
    -- -$0.49 --
  • What do Analysts Say About HOOK or VIGL?

    HOOKIPA Pharma has a consensus price target of $2.00, signalling upside risk potential of 65.29%. On the other hand Vigil Neuroscience has an analysts' consensus of $9.52 which suggests that it could grow by 18.91%. Given that HOOKIPA Pharma has higher upside potential than Vigil Neuroscience, analysts believe HOOKIPA Pharma is more attractive than Vigil Neuroscience.

    Company Buy Ratings Hold Ratings Sell Ratings
    HOOK
    HOOKIPA Pharma
    0 1 0
    VIGL
    Vigil Neuroscience
    0 8 0
  • Is HOOK or VIGL More Risky?

    HOOKIPA Pharma has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison Vigil Neuroscience has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HOOK or VIGL?

    HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vigil Neuroscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. Vigil Neuroscience pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HOOK or VIGL?

    HOOKIPA Pharma quarterly revenues are $2M, which are larger than Vigil Neuroscience quarterly revenues of --. HOOKIPA Pharma's net income of -$15.4M is higher than Vigil Neuroscience's net income of -$22.4M. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while Vigil Neuroscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 1.62x versus -- for Vigil Neuroscience. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HOOK
    HOOKIPA Pharma
    1.62x -- $2M -$15.4M
    VIGL
    Vigil Neuroscience
    -- -- -- -$22.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will CoreWeave Stock Be in 1 Year?
Where Will CoreWeave Stock Be in 1 Year?

When CoreWeave (NASDAQ: CRWV) slipped below its $40 IPO price…

Where Will Cisco Stock Be In 1 Year?
Where Will Cisco Stock Be In 1 Year?

Cisco Systems (NASDAQ: CSCO) rarely makes the front page of fintech…

Why Did David Tepper Sell Meta Stock?
Why Did David Tepper Sell Meta Stock?

Throughout 2024, David Tepper of Appaloosa Holdings sold more than…

Stock Ideas

Buy
68
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 55x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
79
RYTM alert for Jul 10

Rhythm Pharmaceuticals [RYTM] is up 0.07% over the past day.

Sell
48
BGL alert for Jul 10

Blue Gold [BGL] is down 17.19% over the past day.

Buy
82
VRNA alert for Jul 10

Verona Pharma PLC [VRNA] is up 0.07% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock